(NASDAQ: PCVX) Vaxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.
Vaxcyte's earnings in 2026 is -$766,628,000.On average, 12 Wall Street analysts forecast PCVX's earnings for 2026 to be -$1,015,358,147, with the lowest PCVX earnings forecast at -$1,186,162,831, and the highest PCVX earnings forecast at -$628,644,137. On average, 11 Wall Street analysts forecast PCVX's earnings for 2027 to be -$987,221,716, with the lowest PCVX earnings forecast at -$1,211,550,383, and the highest PCVX earnings forecast at -$781,271,680.
In 2028, PCVX is forecast to generate -$811,797,188 in earnings, with the lowest earnings forecast at -$984,472,837 and the highest earnings forecast at -$681,534,870.